结肠镜检查与按分子肿瘤亚型划分的结直肠癌风险降低:一项基于人群的病例对照研究
该研究为德国基于人群的病例对照研究,纳入2132例首次诊断结直肠癌患者和2486例无结直肠癌对照,评估既往结肠镜检查与不同分子亚型结直肠癌风险的关联。结果显示结肠镜检查总体降低结直肠癌风险,但微卫星不稳定、CpG岛甲基化表型高、BRAF突变、KRAS突变及传统通路等亚型的风险降低程度弱于对应亚型。
要点
- 结肠镜检查对微卫星不稳定结直肠癌的风险降低弱于非微卫星不稳定结直肠癌。
- 结肠镜检查对CpG岛甲基化表型高、BRAF突变结直肠癌的风险降低弱于对应亚型。
- 检出腺瘤或增生性息肉后的结肠镜检查对无蒂锯齿状通路、微卫星不稳定和BRAF突变亚型未见风险降低。
核心结论
- 结肠镜检查降低结直肠癌风险的程度因分子肿瘤标志物和通路亚型而异,微卫星不稳定、CpG岛甲基化表型高、BRAF突变、KRAS突变及无蒂锯齿状通路等亚型的风险降低较弱。
- 该研究扩展了对既往报道的近端与远端结直肠癌风险降低差异的分子理解,并可能为改进相关前驱病变的及时检出策略提供重要信息。
研究设计与样本
- 这是一项来自德国的基于人群的病例对照研究,纳入2132例首次诊断结直肠癌且有主要分子肿瘤标志物信息的患者和2486例无结直肠癌的对照参与者。
- 参与者特征通过标准化问卷收集,既往结肠镜检查信息来自医疗记录。
- 采用多项逻辑回归计算既往结肠镜检查与结直肠癌亚型关联的调整比值比(OR)和95%置信区间(CI)。
主要发现
- 结肠镜检查后微卫星不稳定结直肠癌的OR为0.70(95% CI 0.50-0.97),非微卫星不稳定结直肠癌的OR为0.28(95% CI 0.24-0.33)。
- 结肠镜检查后CpG岛甲基化表型高结直肠癌的OR为0.45(95% CI 0.34-0.59),CpG岛甲基化表型低/阴性结直肠癌的OR为0.29(95% CI 0.25-0.34)。
- 结肠镜检查后BRAF突变结直肠癌的OR为0.62(95% CI 0.42-0.91),BRAF非突变结直肠癌的OR为0.30(95% CI 0.25-0.35)。
- 结肠镜检查后KRAS非突变结直肠癌的OR为0.34(95% CI 0.29-0.40),KRAS突变结直肠癌的OR为0.26(95% CI 0.20-0.32)。
- 结肠镜检查后无蒂锯齿状通路结直肠癌的OR为0.57(95% CI 0.36-0.91),传统通路结直肠癌的OR为0.30(95% CI 0.25-0.37)。
关键数值与推荐
- 微卫星不稳定结直肠癌OR 0.70(95% CI 0.50-0.97) vs 非微卫星不稳定结直肠癌OR 0.28(95% CI 0.24-0.33)。
- CpG岛甲基化表型高结直肠癌OR 0.45(95% CI 0.34-0.59) vs CpG岛甲基化表型低/阴性结直肠癌OR 0.29(95% CI 0.25-0.34)。
- BRAF突变结直肠癌OR 0.62(95% CI 0.42-0.91) vs BRAF非突变结直肠癌OR 0.30(95% CI 0.25-0.35)。
- KRAS非突变结直肠癌OR 0.34(95% CI 0.29-0.40) vs KRAS突变结直肠癌OR 0.26(95% CI 0.20-0.32)。
- 无蒂锯齿状通路结直肠癌OR 0.57(95% CI 0.36-0.91) vs 传统通路结直肠癌OR 0.30(95% CI 0.25-0.37)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In previous studies, the protective effect of colonoscopy was generally stronger for distal colorectal cancer than for proximal colorectal cancer (CRC). This study aimed to investigate whether reduction of CRC risk through colonoscopy varies according to major tumor markers and pathways of CRC. METHODS: This is a population-based case-control study from Germany, including 2,132 patients with a first diagnosis of CRC and information on major molecular tumor markers and 2,486 control participants without CRC. Detailed participant characteristics were collected by standardized questionnaires. Information on previous colonoscopy was derived from medical records. Polytomous logistic regression was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association between previous colonoscopy and subtypes of CRC. RESULTS: Overall, we observed strong risk reduction of CRC after colonoscopy that was weaker for microsatellite instable (MSI) than for non-MSI CRC (OR 0.70, 95% CI 0.50-0.97 vs OR 0.28, 95% CI 0.24-0.33), for CpG island methylator phenotype high CRC than for CpG island methylator phenotype low/negative CRC (OR 0.45, 95% CI 0.34-0.59 vs OR 0.29, 95% CI 0.25-0.34), for BRAF-mutated than for BRAF nonmutated CRC (OR 0.62, 95% CI 0.42-0.91 vs OR 0.30, 95% CI 0.25-0.35), for KRAS nonmutated than for KRAS-mutated CRC (OR 0.34, 95% CI 0.29-0.40 vs OR 0.26, 95% CI 0.20-0.32), and for CRC classified into the sessile serrated pathway than for CRC of the traditional pathway (OR 0.57, 95% CI 0.36-0.91 vs OR 0.30, 95% CI 0.25-0.37). After colonoscopy with the detection of adenomas or hyperplastic polyps, no risk reduction was found for sessile serrated pathway CRC, MSI, and BRAF-mutated subtypes. DISCUSSION: Our study extends the molecular understanding of existing differences in risk reduction of proximal and distal CRCs reported by previous studies and may imply important information for improving strategies for timely detection of relevant precursors.
引用
- Hoffmeister M, Bläker H, Jansen L, et al. Colonoscopy and Reduction of Colorectal Cancer Risk by Molecular Tumor Subtypes: A Population-Based Case-Control Study. Am J Gastroenterol. 2020. PMID: 32858564. doi:10.14309/ajg.0000000000000819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。